I N D U S T R Y I N V E S T I G A T I O N
The pivotal study, titled:‘ Effects of adjuvant hyperbaric oxygen therapy and real-time fluorescent imaging on deep sternal wound infection: a retrospective study’, published in the Journal of Wound Care( 2025), revealed that incorporating MolecuLight’ s real-time fluorescence imaging into the treatment protocol for DSWI led to faster infection resolution, a dramatic reduction in antibiotic use and associated costs, shorter and less intensive hospital stays, and significantly lower rates of dangerous complications, including reinfection and osteomyelitis, when contrasted with standard care employing hyperbaric oxygen therapy( HBOT).
Key findings that underscore the power of MolecuLight imaging:
• Significantly improved infection control: MolecuLight-guided treatment increased the likelihood of white blood cell counts returning to normal within 7 days by 26- fold( 72.7 % versus 9.1 %) and C-reactive protein levels normalising within 14 days by 7-fold( 78.8 % versus 31.8 %) in comparison to HBOT.
• Reduced antibiotic use and costs: The MolecuLight group required antibiotics for a significantly shorter duration( 22 days vs. 29.5 days), leading to nearly twothirds lower antibiotic costs( US $ 573.57 versus US $ 1,643.78).
• Faster healing and reduced burden on healthcare systems: Patients treated with MolecuLight experienced ICU stays that were 70 % shorter( 3 days vs. 10 days) and achieved complete wound healing 20 % faster( 40 days vs. 50 days).
• Significantly lower risk of complications: The use of MolecuLight imaging was associated with an 82 % lower likelihood of in-hospital wound reinfection and an
www. intelligenthealth. tech 41